Do Traders Think Lantern Pharma Inc (LTRN) Can Turn Around Wednesday?

Overall market sentiment has been down on Lantern Pharma Inc (LTRN) stock lately. LTRN receives a Bearish rating from InvestorsObserver Stock Sentiment Indicator.

Lantern Pharma Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on LTRN!

See Full LTRN Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With LTRN Stock Today?

Lantern Pharma Inc (LTRN) stock has gained 0.35% while the S&P 500 is lower by -0.62% as of 10:15 AM on Wednesday, Oct 25. LTRN has gained $0.01 from the previous closing price of $2.84 on volume of 3,835 shares. Over the past year the S&P 500 has gained 11.16% while LTRN is lower by -37.91%. LTRN lost -$1.31 per share in the over the last 12 months. To see InvestorsObserver's Sentiment Score for Lantern Pharma Inc click here.

More About Lantern Pharma Inc

Lantern Pharma Inc is a clinical-stage biotechnology company. It is focused on leveraging artificial intelligence (A.I), machine learning and genomic data to streamline the drug development process and to identify the patients that will benefit from targeted oncology therapies. The firm's pipeline of development programs involves four drug candidates and an Antibody Drug Conjugate (ADC) program directed towards eight therapeutic targets. Its A.I. platform, known as RADR, includes more than 18 billion data points, and uses big data analytics and machine learning to rapidly uncover biologically relevant genomic signatures correlated to drug response, and then identify the cancer patients that we believe may benefit most from our compounds. Click Here to get the full Stock Report for Lantern Pharma Inc stock.